Nintedanib (BIBF 1120): Triple Angiokinase Inhibitor for Cancer and Fibrosis Research

Executive Summary: Nintedanib (BIBF 1120) is an orally active, indolinone-derived inhibitor that blocks VEGFR1-3, PDGFRα/β, and FGFR1-3 signaling at nanomolar concentrations (IC50: 13–108 nM), disrupting angiogenesis essential for tumor and fibrotic disease progression (Pladevall-Morera et al., 2022). It induces apoptosis and DNA fragmentation in hepatocellular carcinoma cell lines at clinically relevant doses. ATRX-deficient high-grade glioma models show increased sensitivity to multi-targeted RTK and PDGFR inhibitors such as Nintedanib. The compound is insoluble in water/ethanol but highly soluble in DMSO (>10 mM); stock solutions remain stable at -20°C for several months. Nintedanib is supplied by APExBIO as a solid (SKU A8252), supporting reliable translational and preclinical workflows [Product page].

Biological Rationale

Angiogenesis—the formation of new blood vessels—is critical for tumor growth and fibrotic tissue remodeling. Tumors and fibrotic lesions exploit vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and fibroblast growth factor (FGF) pathways to sustain proliferation and evade therapeutic interventions. Overexpression or amplification of VEGFR1-3, PDGFRα/β, and FGFR1-3 is common in cancers such as non-small cell lung cancer (NSCLC), ovarian, colorectal, and hepatocellular carcinomas [DOI]. In idiopathic pulmonary fibrosis, aberrant activation of these receptors drives fibroblast proliferation and extracellular matrix deposition. Multi-targeted inhibition of these receptor tyrosine kinases (RTKs) is a validated strategy to halt disease progression in both oncology and fibrosis research. ATRX-deficient gliomas, which display heightened RTK dependency, have emerged as an especially relevant indication for triple angiokinase inhibitors [DOI].

Mechanism of Action of Nintedanib (BIBF 1120)

Nintedanib (BIBF 1120) competitively inhibits the ATP-binding sites of VEGFR1-3, PDGFRα/β, and FGFR1-3, blocking downstream phosphorylation cascades essential for endothelial cell proliferation, migration, and survival. The compound exhibits IC50 values of 13–34 nM for VEGFRs, 37–108 nM for FGFRs, and 59–65 nM for PDGFRs in kinase assays. By preventing receptor autophosphorylation, Nintedanib disrupts angiogenic signaling, leading to reduced vascularization in tumors and fibrotic tissues [APExBIO Product Page]. In hepatocellular carcinoma cell lines, Nintedanib induces apoptosis as evidenced by DNA fragmentation and increased caspase activity. In ATRX-deficient glioma cells, RTK and PDGFR inhibition results in heightened cytotoxicity relative to ATRX-wildtype controls, supporting biomarker-driven applications [DOI].

Evidence & Benchmarks

• Nintedanib inhibits VEGFR1-3, PDGFRα/β, and FGFR1-3 with IC50 values between 13 and 108 nM under in vitro kinase assay conditions (pH 7.4, 25°C) (APExBIO).
• ATRX-deficient high-grade glioma cells show increased sensitivity to multi-targeted RTK and PDGFR inhibitors such as Nintedanib, leading to enhanced cell death versus ATRX-wildtype lines (Pladevall-Morera et al., 2022).
• Oral administration of Nintedanib in xenograft models (10–50 mg/kg, daily dosing) results in significant tumor growth reduction and volume decrease in NSCLC and hepatocellular carcinoma models (crizotinib.biz).
• Combination therapy with Nintedanib and temozolomide in ATRX-mutant glioma models produces pronounced cytotoxicity and extends therapeutic window (Pladevall-Morera et al., 2022).
• In vitro, Nintedanib induces apoptosis and DNA fragmentation in hepatocellular carcinoma cells at clinically relevant doses (1–10 µM, 24–48 h, DMSO vehicle) (APExBIO).

For a broader perspective on the biological rationale and evolving clinical strategies, see Nintedanib (BIBF 1120): Strategic Insights and Mechanistic Advances, which contextualizes APExBIO's offering within emerging paradigms. This article extends those insights by focusing on ATRX biomarker-driven applications and concrete workflow recommendations.

Applications, Limits & Misconceptions

Applications: Nintedanib is validated as an antiangiogenic agent for cancer therapy and idiopathic pulmonary fibrosis treatment. It is widely used in non-small cell lung cancer research and in preclinical models of ovarian, colorectal, and hepatocellular carcinomas. Its efficacy in ATRX-deficient tumor models supports its use in precision oncology workflows. The compound's pro-apoptotic and anti-proliferative effects are robustly documented across multiple cell lines and xenograft systems.

Common Pitfalls or Misconceptions

• Nintedanib is not water- or ethanol-soluble: Attempting to dissolve the compound in aqueous or alcoholic buffers leads to precipitation and loss of activity; use DMSO (>10 mM) and warm/sonicate as needed (APExBIO).
• Nintedanib is not a selective VEGFR inhibitor: It targets VEGFR, PDGFR, and FGFR families, so off-target kinase effects should be considered in experimental design (DOI).
• Stock solution instability above -20°C: Storage at higher temperatures may cause degradation; always store solids and solutions at -20°C for maximal shelf-life (APExBIO).
• Limited efficacy in ATRX-wildtype gliomas: Heightened sensitivity is reported in ATRX-deficient models; do not assume equivalent potency in ATRX-wildtype backgrounds (DOI).
• Not suitable for direct clinical use from research-grade stocks: Only GMP-grade formulations are appropriate for human administration; research-grade Nintedanib (A8252) is for preclinical and in vitro work.

For practical assay guidance and tips on maintaining data fidelity, see Nintedanib (BIBF 1120): Data-Driven Solutions for Cancer Research. This article updates assay integration recommendations based on the latest ATRX-deficient glioma data.

Workflow Integration & Parameters

Nintedanib (BIBF 1120) is supplied by APExBIO as a solid with molecular weight 539.62 (C31H33N5O4). Dissolve in DMSO to make stock solutions (>10 mM), warming and sonication recommended. Stock aliquots are stable for several months at -20°C; avoid repeated freeze-thaw cycles. For in vitro studies, typical working concentrations range from 10 nM to 10 µM in DMSO (final DMSO ≤0.1%). For in vivo xenograft models, validated dosing is 10–50 mg/kg, oral gavage, daily or BID, depending on model. Common adverse effects (in vivo) include diarrhea, nausea, vomiting, and lethargy, consistent with human safety profiles. ATRX status should be determined in cell lines or tumor models to stratify sensitivity. For workflow-specific mechanistic details relevant to ATRX-deficient models, see Nintedanib (BIBF 1120): Mechanistic Precision and Strategy; this article clarifies the added value of integrating ATRX biomarker analysis for experimental planning.

Conclusion & Outlook

Nintedanib (BIBF 1120) is a validated triple angiokinase inhibitor with robust antiangiogenic and pro-apoptotic effects in cancer and fibrosis models. Its nanomolar potency and demonstrated efficacy in ATRX-deficient gliomas establish it as a key tool for translational research. Workflow integration requires attention to solubility and storage parameters. Future research will benefit from biomarker-driven stratification and rational combination therapies. Sourcing from APExBIO ensures quality and batch consistency for high-impact preclinical studies. For detailed specifications and ordering, refer to the Nintedanib (BIBF 1120) product page.